Compare AbCellera Biologics Inc (ABCL) vs Smith & Nephew plc (SNN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Smith & Nephew plc — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Smith & Nephew plc trades at $30.06 (market cap $12.73B). The key difference: Smith & Nephew plc is far larger — about 5.4× AbCellera Biologics Inc's market cap, and Smith & Nephew plc pays a 2.57% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SNN | |
|---|---|---|
Market Cap | $2.35B | $12.73B |
Sector | Health | Health |
52-Week High | $8.12 | $38.70 |
52-Week Low | $2.78 | $28.73 |
Enterprise Value | $1.99B | $15.50B |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Smith & Nephew (SNN) trades at $30.48, up 0.76% with a bullish technical signal. The company shows improving fundamentals with revenue growing from $5.8B in 2024 to $6.2B in 2025 and net income margin expanding to 10.13%. Recent product launches in robotics and wound care demonstrate innovation momentum. Technical indicators show support at $30 and resistance at $31, with moving averages signaling bullish momentum.
SNN presents a mixed investment case with strong revenue growth and margin expansion offset by inconsistent earnings performance. The company's $500M share buyback and positive 2026 outlook provide support, but recent earnings misses and cautious analyst sentiment (68% hold rating) suggest near-term caution. Key risks include execution challenges and competitive pressures in medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
